The effect of different anticoagulants on thrombin generation

Blood Coagulation and Fibrinolysis

Volumn 17, Issue 2, 2006, Pages 131-137

  Petros, Sirak ^a   Siegemund, Thomas ^a   Siegemund, Annelie ^a,b   Engelmann, Lothar ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b Labor Dr Reising Ackermann und Partner   (Germany)

Author keywords

Anticoagulation; Platelets; Thrombin generation

Indexed keywords

ANTICOAGULANT AGENT; FONDAPARINUX; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN; THROMBOPLASTIN;

ADULT; ANTICOAGULATION; ARTICLE; DOSE RESPONSE; DRUG MECHANISM; FEMALE; HUMAN; IC 50; MALE; NORMAL HUMAN; PRIORITY JOURNAL; THROMBOCYTE COUNT;

ADULT; ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HIRUDINS; HUMANS; MALE; MIDDLE AGED; POLYSACCHARIDES; THROMBIN; THROMBIN TIME;

EID: 33646089867     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mbc.0000214708.73374.ce     Document Type: Article

References (39)

1. Salzet M. Leech thrombin inhibitors. Curr Pharm Des 2002; 8:493-503.
2. Adams TE, Everse SJ, Mann KG. Predicting the pharmacology of thrombin inhibitors. J Thromb Haemost 2003; 1:1024-1027.
3. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:1883-2033.
4. Samama MM, Gerotziafas GT, Elalamy I, Horellou MH, Conrad J. Biochemistry and clinical pharmacology of new anticoagulant agents. Pathophysiol Haemost Thromb 2002; 32:218-224.
5. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119:648-948.
6. Sephton V, Farquharson RG, Topping J, Quenby SM, Cowan C, Back DJ, Toh CH. A longitudinal study of maternal dose response to low molecular weight heparin in pregnancy. Obstet Gynecol 2003; 101:1307-1311.
7. Ho SH, Wu JK, Hamilton DP, Dix DB, Wadsworth LD. An assessment of published pediatric dosage guidelines for enoxaparin: a retrospective review. J Pediatr Hematol Oncol 2004; 26:561-566.
8. Siguret V, Pautas E, Gouin I. Low molecular weight heparin treatment in elderly subjects with or without renal insufficiency: new insights between June 2002 and March 2004. Curr Opin Pulm Med 2004; 10:366-370.
9. Sutor AH, Chan AK, Massicotte P. Low-molecular-weight heparin in pediatric patients. Semin Thromb Hemost 2004; 30:31-39.
10. Gouin-Thibault I, Pautas E, Siguret V. Safety profile of different low-molecular weight heparins used at therapeutic dose. Drug Saf 2005; 28:333-349.
11. Greer I, Hunt BJ. Low molecular weight heparin in pregnancy: current issues. Br J Haematol 2005; 128:593-601.
12. Beguin S, Welzel D, Al Dieri R, Hemker HC. Conjectures and refutations on the mode of action of heparins. The limited importance of anti-factor Xa activity as a pharmaceutical mechanism and a yardstick for therapy. Haemostasis 1999; 29:170-178.
13. Keularts IM, Hamulyak K, Hemker HC, Beguin S. The effect of DDAVP infusion on thrombin generation in platelet-rich plasma of von Willebrand type 1 and in mild haemophilia A patients. Thromb Haemost 2000; 84:638-642.
14. Hemker HC, Giesen PL, Ramjee M, Wagenvoord R, Beguin S. The thrombogram: monitoring thrombin generation in platelet-rich plasma. Thromb Haemost 2000; 83:589-591.
15. Faber CG, Lodder J, Kessels F, Troost J. Thrombin generation in platelet-rich plasma as a tool for the detection of hypercoagulability in young stroke patients. Pathophysiol Haemost Thromb 2003; 33:52-58.
16. Al Dieri R, Alban S, Beguin S, Hemker HC. Thrombin generation for the control of heparin treatment, comparison with the activated partial thromboplastin time. J Thromb Haemost 2004; 2:1395-1401.
17. Ramjee MK. The use of fluorogenic substrates to monitor thrombin generation for the analysis of plasma and whole blood coagulation. Anal Biochem 2000; 277:11-18.
18. rd ed. New York: Marcel Dekker; 2004, pp. 397-436.
19. Samama MM, Gerotziafas GT. Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux). Thromb Res 2003; 109:1-11.
20. Hemker HC, Willems GM, Béguin S. A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. Thromb Haemost 1986; 56:9-17.
21. Kessels H, Willems G, Hemker HC. Analysis of thrombin generation in plasma. Comput Biol Med 1994; 24:277-288.
22. Siegemund T, Petros S, Siegemund A, Scholz U, Engelmann L. Thrombin generation in severe haemophilia A and B: the endogenous thrombin potential in platelet-rich plasma. Thromb Haemost 2003; 90:781-786.
23. Wegert W, Graff J, Kaiser D, Breddin HK, Klinkhardt U, Harder S. Effects of antiplatelet agents on platelet-induced thrombin generation. Int J Clin Pharmacol Ther 2002; 40:135-141.
24. Gerotziafas GT, Chakroun T, Depasse F, Arzoglu P, Samama MM, Elalamy I. The role of platelets and recombinant factor VIIa on thrombin generation, platelet activation and clot formation. Thromb Haemost 2004; 91:977-985.
25. Gerotziafas GT, Depasse F, Chakroun T, Van Dreden P, Samama MM, Elalamy I. Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma. Blood Coagul Fibrinolysis 2004; 15:149-156.
26. Boström SL, Hansson GF, Sarich TC, Wolzt M. The inhibitory effect of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, compared with enoxaparin and r-hirudin on ex vivo thrombin generation in human plasma. Thromb Res 2004; 113:85-91.
27. Beguin S, Keularts I. On the coagulation of platelet-rich plasma. Physiological mechanism and pharmacological consequences. Haemostasis 1999; 29:50-57.
28. Halfon S, Malinowski J, Sinha U. Effect of anticoagulants and antiplatelet agents on platelet-mediated thrombin generation. Blood Coagul Fibrinolysis 2002; 13:715-724.
29. Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 2002; 22:1381-1389.
30. Spencer FA, Ball SP, Zhang Q, Liu L, Benoit S, Becker RC. Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by factor-Xa neutralization. J Thromb Thrombolysis 2000; 9:223-228.
31. Eagle H. Studies on blood coagulation. I. The role of prothrombin and of platelets in the formation of thrombin. J Gen Physiol 1935; 18:531-545.
32. Vanschoonbeek K, Feijge MA, Van Kampen RJ, Kenis H, Hemker HC, Giesen PL, Heemskerk JW. Initiating and potentiating role of platelets in tissue factor-induced thrombin generation in the presence of plasma: subject-dependent variation in thrombogram characteristics. J Thromb Haemost 2004; 2:476-484.
33. Lisman T, Adelmeijer J, Nieuwenhuis HK, de Groot PG. Enhancement of fibrinolytic potential in vitro by anticoagulant drugs targeting activated factor X, but not by those inhibiting thrombin or tissue factor. Blood Coagul Fibrinolysis 2003; 14:557-562.
34. Kam PCA. Kaur N, Thong CL. Direct thrombin inhibitors: pharmacology and clinical relevance. Anaesthesia 2005; 60:565-574.
35. Di Nisio M, Middeldorp S, Büller HR. Direct thrombin inhibitors. N Engl J Med 2005; 353:1028-1040.
36. Hemker HC, Choay J, Beguin S. Free factor Xa is on the main pathway of thrombin generation in clotting plasma. Biochim Biophys Acta 1989; 992:409-411.
37. Herault JP, Bernat A, Pflieger AM, Lormeau JC, Herbert JM. Comparative effects of two direct and indirect factor Xa inhibitors on free and clot-bound prothrombinase. J Pharmacol Exp Ther 1997; 283:16-22.
38. Bendetowicz AV, Kai H, Knebel R, Caplain H, Hemker HC, Lindhout T, Beguin S. The effect of subcutaneous injection of unfractionated and low molecular weight heparin on thrombin generation in platelet rich plasma: a study in human volunteers. Thromb Haemost 1994; 72:705-712.
39. Boström SL, Hansson GF, Kjaer M, Sarich TC. Effects of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, and dalteparin on the endogenous thrombin potential in venous blood from healthy male subjects. Blood Coagul Fibrinolysis 2003; 14:457-462.